▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3020 by analyst upside · 2026-11-13
WST
West Pharmaceutical Services, Inc.
Healthcare · Market Cap $29B · P/E 46.2x
ANALYST PRICE TARGET
+14.5%
implied upside to consensus target
Current Price $411.3
Consensus Target $471.0
Bull Target $500.0
Bear Target $340.0
Analysts Covering 15
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
11
Hold
0
Sell
1
52-Week Low $223.83
52-Week High $438.27
YTD Return +49.2%
FUNDAMENTALS
Market Cap $29B
P/E Ratio (TTM) 46.2x
Forward P/E 39.6x
EPS (TTM) $8.91
PEG Ratio 3.00
Dividend Yield 0.25%
Revenue (TTM) $3.4B
Profit Margin 18.8%
52-WEEK RANGE
52-Week Low $223.83
52-Week High $438.27
Current Price $411.3
Bear Target $340.0
Bull Target $500.0
● Now $411.3 ● Target $471.0
TRADING DATA
Avg Volume 610K
YTD Return +49.2%
Analyst Count 15
Consensus Buy
Upside to Target +14.5%
Last Updated 2026-11-13

ANALYST SUMMARY

West Pharmaceutical Services, Inc. (WST) is currently trading at $411.3 with a Wall Street consensus price target of $471.0, implying potential upside of 14.5% over the next 12 months. 15 analysts currently cover WST, with a consensus rating of Buy - 93% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $500.0, while the most cautious has a target of $340.0.

WST operates in the Healthcare sector with a market capitalisation of $29B. The stock is up 49.2% year-to-date and is currently trading near the upper end of its 52-week range of $223.83 – $438.27.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for WST, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Citigroup - Reiterated
Buy → Buy 2026-10-30 Building track record
TD Cowen - Reiterated
Buy → Buy 2026-10-30 Building track record
Barclays - Reiterated
Overweight → Overweight 2026-10-30 Building track record
Evercore ISI Group - Reiterated
Outperform → Outperform 2026-10-30 Building track record
TD Cowen - Reiterated
Buy → Buy 2026-10-13 Building track record
Barclays - Reiterated
Overweight → Overweight 2026-10-07 Building track record
Morgan Stanley ↑ Upgrade
Equal-Weight → Overweight 2026-09-22 Building track record
UBS - Reiterated
Buy → Buy 2026-09-09 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
65
out of 100
Coverage depth
21/30
Consensus clarity
22/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →